Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
Purpose: next-generation sequencing based comprehensive genomic profiling (CGP) is becoming common practice. Although numerous studies have shown its feasibility to identify actionable genomic alterations in most patients, its clinical impact as part of routine management across all cancers in the c...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/5/1156 |
id |
doaj-92f77aac00854f7c8a247b42d8cbc4fc |
---|---|
record_format |
Article |
spelling |
doaj-92f77aac00854f7c8a247b42d8cbc4fc2020-11-25T03:13:19ZengMDPI AGCancers2072-66942020-05-01121156115610.3390/cancers12051156Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical PracticeAditi P. Singh0Elaine Shum1Lakshmi Rajdev2Haiying Cheng3Sanjay Goel4Roman Perez-Soler5Balazs Halmos6Division of Hematology and Oncology, University of Pennsylvania/Abramson Cancer Center, Philadelphia, PA 19104, USADivision of Medical Oncology and Hematology, NYU Langone Perlmutter Cancer Center, New York, NY 10016, USADepartment of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10467, USADepartment of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10467, USADepartment of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10467, USADepartment of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10467, USADepartment of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10467, USAPurpose: next-generation sequencing based comprehensive genomic profiling (CGP) is becoming common practice. Although numerous studies have shown its feasibility to identify actionable genomic alterations in most patients, its clinical impact as part of routine management across all cancers in the community remains unknown. Methods: we conducted a retrospective study of all patients that underwent CGP as part of routine cancer management from January 2013 to June 2017 at an academic community-based NCI-designated cancer center. CGP was done in addition to established first tier reflex molecular testing as per national guidelines (e.g., <i>EGFR</i>/<i>ALK</i> for non-small cell lung cancer (NSCLC) and extended-<i>RAS</i> for colorectal cancer). Results: 349 tests were sent for CGP from 333 patients and 95% had at least one actionable genomic alteration reported. According to the reported results, 23.2% had a Food and Drug Administration (FDA) approved therapy available, 61.3% had an off-label therapy available and 77.9% were potentially eligible for a clinical trial. Treatment recommendations were also reviewed within the OncoKB database and 47% of them were not clinically validated therapies. The CGP results led to treatment change in only 35 patients (10%), most commonly in NSCLC. Nineteen of these patients (54% of those treated and 5% of total) had documented clinical benefit with targeted therapy. Conclusion: we demonstrate that routine use of CGP in the community across all cancer types detects potentially actionable genomic alterations in a majority of patients, however has modest clinical impact enriched in the NSCLC subset.https://www.mdpi.com/2072-6694/12/5/1156comprehensive genomic profilingmolecular genotyping |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Aditi P. Singh Elaine Shum Lakshmi Rajdev Haiying Cheng Sanjay Goel Roman Perez-Soler Balazs Halmos |
spellingShingle |
Aditi P. Singh Elaine Shum Lakshmi Rajdev Haiying Cheng Sanjay Goel Roman Perez-Soler Balazs Halmos Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice Cancers comprehensive genomic profiling molecular genotyping |
author_facet |
Aditi P. Singh Elaine Shum Lakshmi Rajdev Haiying Cheng Sanjay Goel Roman Perez-Soler Balazs Halmos |
author_sort |
Aditi P. Singh |
title |
Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice |
title_short |
Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice |
title_full |
Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice |
title_fullStr |
Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice |
title_full_unstemmed |
Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice |
title_sort |
impact and diagnostic gaps of comprehensive genomic profiling in real-world clinical practice |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2020-05-01 |
description |
Purpose: next-generation sequencing based comprehensive genomic profiling (CGP) is becoming common practice. Although numerous studies have shown its feasibility to identify actionable genomic alterations in most patients, its clinical impact as part of routine management across all cancers in the community remains unknown. Methods: we conducted a retrospective study of all patients that underwent CGP as part of routine cancer management from January 2013 to June 2017 at an academic community-based NCI-designated cancer center. CGP was done in addition to established first tier reflex molecular testing as per national guidelines (e.g., <i>EGFR</i>/<i>ALK</i> for non-small cell lung cancer (NSCLC) and extended-<i>RAS</i> for colorectal cancer). Results: 349 tests were sent for CGP from 333 patients and 95% had at least one actionable genomic alteration reported. According to the reported results, 23.2% had a Food and Drug Administration (FDA) approved therapy available, 61.3% had an off-label therapy available and 77.9% were potentially eligible for a clinical trial. Treatment recommendations were also reviewed within the OncoKB database and 47% of them were not clinically validated therapies. The CGP results led to treatment change in only 35 patients (10%), most commonly in NSCLC. Nineteen of these patients (54% of those treated and 5% of total) had documented clinical benefit with targeted therapy. Conclusion: we demonstrate that routine use of CGP in the community across all cancer types detects potentially actionable genomic alterations in a majority of patients, however has modest clinical impact enriched in the NSCLC subset. |
topic |
comprehensive genomic profiling molecular genotyping |
url |
https://www.mdpi.com/2072-6694/12/5/1156 |
work_keys_str_mv |
AT aditipsingh impactanddiagnosticgapsofcomprehensivegenomicprofilinginrealworldclinicalpractice AT elaineshum impactanddiagnosticgapsofcomprehensivegenomicprofilinginrealworldclinicalpractice AT lakshmirajdev impactanddiagnosticgapsofcomprehensivegenomicprofilinginrealworldclinicalpractice AT haiyingcheng impactanddiagnosticgapsofcomprehensivegenomicprofilinginrealworldclinicalpractice AT sanjaygoel impactanddiagnosticgapsofcomprehensivegenomicprofilinginrealworldclinicalpractice AT romanperezsoler impactanddiagnosticgapsofcomprehensivegenomicprofilinginrealworldclinicalpractice AT balazshalmos impactanddiagnosticgapsofcomprehensivegenomicprofilinginrealworldclinicalpractice |
_version_ |
1724647507677413376 |